The researchers at the Cancer Research UK Manchester Institute discovered that the ties which lash cells together — controlled by a protein called TIAM1 — are chopped up when cell maintenance work goes wrong. …
Cancer stem cells are particularly difficult to eradicate and are at the heart of why it is so hard to more effectively treat cancer patients, as the post-treatment survival of cancer stem cells drives tumor recurrence, the systemic spread of cancer and, ultimately, treatment failure. The researchers, based at the University’s Institute of Cancer Sciences and the Cancer Research UK Manchester Institute — both part of the Manchester Cancer Research Centre — investigated the role of mitochondria which produce and release energy within cells…
A Cancer Research UK-funded UK study led by researchers at the University of Leicester, with key collaborators from the Universities of Glasgow, Manchester and Edinburgh, has discovered that adding the investigational agent cediranib, which has been developed by the multinational pharmaceutical and biologics company AstraZeneca, to standard chemotherapy may be beneficial for patients with metastatic or recurrent cervical cancer and could pave the way for future treatment of the disease. Professor Paul Symonds from the Department of Cancer Studies and Molecular Medicine at the University of Leicester and a consultant at Leicester’s Hospitals, explained: “Cancers develop their own blood supply and cancers of the cervix with a well-developed blood supply can have a particularly bad outcome for the patient. “One of the substances which increase new blood vessels in cervical cancer is Vascular Endothelial Growth Factor (VEGF). The experimental drug cediranib blocks the receptor for VEGF in the cancer, potentially limiting its growth in the body. …
The researchers, based at The University of Manchester and funded by MedImmune, the global biologics research and development arm of AstraZeneca, and Cancer Research UK, found that combining the two treatments helped the immune system hunt down and destroy cancer cells that weren’t killed by the initial radiotherapy in mice with breast, skin and bowel cancers. Radiotherapy is a very successful treatment for many forms of cancer, but in cancer cells that it doesn’t kill it can switch on a ‘flag’ on their surface, called PD-L1, that tricks the body’s defences into thinking that cancerous cells pose no threat. The immunotherapy works by blocking these ‘flags’ to reveal the true identity of cancer cells, allowing the immune system to see them for what they are and destroy them…
“Reports of lung cancers bearing mutations in BRAF have generated considerable interest because these mutations may be associated with increased sensitivity to BRAF tyrosine-kinase inhibiting agents,” says lead author Dr David Planchard, pulmonary oncologist at the Gustav-Roussy Cancer Campus, Paris, France. Planchard says studies suggest that activating BRAF mutations are present in around 2% of lung carcinomas — approximately 80% of which are V600E mutations. The BRAF V600E mutations are frequently associated with shorter disease-free, overall survival, and lower response rates to platinum-based chemotherapy. …
Cancer Research UK scientists at The University of Manchester found that chemical signals produced by a type of immune cell, called macrophages, also act as a survival signal for melanoma cells. …
New research based on data from 21 centers shows that many more women approached their GPs with concerns. Far from these being women with unfounded concerns, it was women with a family history of breast cancer, which translated into appropriate referrals for testing. This research was funded by Breast Cancer Campaign…
Standard treatment for locally advanced non-small cell lung cancer is a combination of radiotherapy and chemotherapy. Traditionally this is planned in a one-size-fits-all manner but the radiation dose may not always be enough to stop tumor growth. The potential to increase the radiation dose to the cancerous tissue varies between patients and depends on the size and location of the tumor in relation to sensitive organs such as the spinal cord and lungs. …
Researchers from the Cancer Research UK Manchester Institute based at The University of Manchester — part of the Manchester Cancer Research Centre — and the Institute of Cancer Research, London, looked at protein kinases, molecules that control various aspects of cellular function. …
Cancer Research UK scientists have discovered that acral melanomas — the rare type of skin cancer that caused reggae musician Bob Marley’s death — are genetically distinct from other more common types of skin cancer, according to a study published in the journal Pigment Cell & Melanoma Research. Acral melanoma most often affects the palms of the hands, soles of the feet, nail-beds and other hairless parts of the skin. Unlike other more common types of melanoma, it’s not caused by UV damage from the sun. The team, from the Cancer Research UK Manchester Institute at The University of Manchester, sequenced the tumours of five patients with acral melanoma and combined this with data from three other patients. …